IL88472A - Interleukin proteins) (SR1-LM in mammals, AND expression vectors that encode them, processes for their preparation and pharmaceutical preparations containing them - Google Patents

Interleukin proteins) (SR1-LM in mammals, AND expression vectors that encode them, processes for their preparation and pharmaceutical preparations containing them

Info

Publication number: IL88472A
Authority: IL; Israel
Prior art keywords: protein; receptor; cells; vas; recombinant
Prior art date: 1987-11-25

Application number

IL8847288A

Other languages

English (en)

Hebrew (he)

Other versions

IL88472A0 (en

Original Assignee

Immunex Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-25

Filing date

1988-11-24

Publication date

1995-03-15

1988-11-24 Application filed by Immunex Corp filed Critical Immunex Corp

1989-06-30 Publication of IL88472A0 publication Critical patent/IL88472A0/xx

1995-03-15 Publication of IL88472A publication Critical patent/IL88472A/en

Links

108050006617 Interleukin-1 receptor Proteins 0.000 title claims abstract description 146
102000019223 Interleukin-1 receptor Human genes 0.000 title claims abstract description 142
239000013604 expression vector Substances 0.000 title claims abstract description 27
239000008194 pharmaceutical composition Substances 0.000 title claims description 4
238000000034 method Methods 0.000 title abstract description 35
230000008569 process Effects 0.000 title abstract description 9
238000004113 cell culture Methods 0.000 claims abstract description 7
108090000623 proteins and genes Proteins 0.000 claims description 105
102000004169 proteins and genes Human genes 0.000 claims description 79
230000027455 binding Effects 0.000 claims description 69
108010002352 Interleukin-1 Proteins 0.000 claims description 52
102000000589 Interleukin-1 Human genes 0.000 claims description 51
230000014509 gene expression Effects 0.000 claims description 46
239000002299 complementary DNA Substances 0.000 claims description 45
108091028043 Nucleic acid sequence Proteins 0.000 claims description 37
150000001413 amino acids Chemical class 0.000 claims description 25
125000003275 alpha amino acid group Chemical group 0.000 claims description 24
239000012634 fragment Substances 0.000 claims description 24
239000013598 vector Substances 0.000 claims description 23
239000002773 nucleotide Substances 0.000 claims description 21
125000003729 nucleotide group Chemical group 0.000 claims description 21
108091026890 Coding region Proteins 0.000 claims description 16
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 15
102000003886 Glycoproteins Human genes 0.000 claims description 11
108090000288 Glycoproteins Proteins 0.000 claims description 11
230000000694 effects Effects 0.000 claims description 10
238000003259 recombinant expression Methods 0.000 claims description 10
230000002103 transcriptional effect Effects 0.000 claims description 8
230000013595 glycosylation Effects 0.000 claims description 7
238000006206 glycosylation reaction Methods 0.000 claims description 7
230000000813 microbial effect Effects 0.000 claims description 7
230000001105 regulatory effect Effects 0.000 claims description 7
230000002068 genetic effect Effects 0.000 claims description 6
230000003834 intracellular effect Effects 0.000 claims description 5
230000001747 exhibiting effect Effects 0.000 claims description 4
238000009396 hybridization Methods 0.000 claims description 4
230000003612 virological effect Effects 0.000 claims description 4
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 2
101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 claims 6
102000055282 human IL1R1 Human genes 0.000 claims 6
239000003085 diluting agent Substances 0.000 claims 2
230000001737 promoting effect Effects 0.000 claims 2
108020004511 Recombinant DNA Proteins 0.000 claims 1
230000009870 specific binding Effects 0.000 claims 1
108020004414 DNA Proteins 0.000 abstract description 37
210000004027 cell Anatomy 0.000 description 144
235000018102 proteins Nutrition 0.000 description 67
102000005962 receptors Human genes 0.000 description 64
108020003175 receptors Proteins 0.000 description 64
241001529936 Murinae Species 0.000 description 46
240000004808 Saccharomyces cerevisiae Species 0.000 description 32
229940024606 amino acid Drugs 0.000 description 27
235000001014 amino acid Nutrition 0.000 description 25
239000000284 extract Substances 0.000 description 25
239000013504 Triton X-100 Substances 0.000 description 22
229920004890 Triton X-100 Polymers 0.000 description 22
239000000203 mixture Substances 0.000 description 21
239000002953 phosphate buffered saline Substances 0.000 description 20
238000000746 purification Methods 0.000 description 20
241000588724 Escherichia coli Species 0.000 description 16
239000000020 Nitrocellulose Substances 0.000 description 16
229920001220 nitrocellulos Polymers 0.000 description 16
239000000243 solution Substances 0.000 description 16
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
239000002609 medium Substances 0.000 description 15
230000010076 replication Effects 0.000 description 14
238000003556 assay Methods 0.000 description 13
239000000499 gel Substances 0.000 description 13
239000000523 sample Substances 0.000 description 13
230000004988 N-glycosylation Effects 0.000 description 12
239000003599 detergent Substances 0.000 description 12
108010052285 Membrane Proteins Proteins 0.000 description 11
108091034117 Oligonucleotide Proteins 0.000 description 11
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 11
239000013612 plasmid Substances 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 11
108020004705 Codon Proteins 0.000 description 10
238000010367 cloning Methods 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
230000001580 bacterial effect Effects 0.000 description 9
210000000170 cell membrane Anatomy 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
239000011159 matrix material Substances 0.000 description 9
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
241000701109 Human adenovirus 2 Species 0.000 description 8
102000018697 Membrane Proteins Human genes 0.000 description 8
239000000872 buffer Substances 0.000 description 8
150000001720 carbohydrates Chemical class 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
150000007523 nucleic acids Chemical group 0.000 description 8
238000004007 reversed phase HPLC Methods 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
108700026244 Open Reading Frames Proteins 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
239000000463 material Substances 0.000 description 7
239000012528 membrane Substances 0.000 description 7
210000004379 membrane Anatomy 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
241000894006 Bacteria Species 0.000 description 6
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
238000001042 affinity chromatography Methods 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
238000011534 incubation Methods 0.000 description 6
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
239000000047 product Substances 0.000 description 6
238000000159 protein binding assay Methods 0.000 description 6
230000007017 scission Effects 0.000 description 6
238000013519 translation Methods 0.000 description 6
101001007681 Candida albicans (strain WO-1) Kexin Proteins 0.000 description 5
108020004635 Complementary DNA Proteins 0.000 description 5
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
108010076504 Protein Sorting Signals Proteins 0.000 description 5
238000013459 approach Methods 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
238000000605 extraction Methods 0.000 description 5
239000008103 glucose Substances 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000008188 pellet Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000009466 transformation Effects 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 4
101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 4
208000002109 Argyria Diseases 0.000 description 4
239000004471 Glycine Substances 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
108700005078 Synthetic Genes Proteins 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
238000007792 addition Methods 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
239000013599 cloning vector Substances 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
238000001514 detection method Methods 0.000 description 4
210000002950 fibroblast Anatomy 0.000 description 4
238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
238000002523 gelfiltration Methods 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
239000003550 marker Substances 0.000 description 4
235000006109 methionine Nutrition 0.000 description 4
125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 description 4
229920002401 polyacrylamide Polymers 0.000 description 4
230000008488 polyadenylation Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000028327 secretion Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
241000894007 species Species 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
241001515965 unidentified phage Species 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 3
102000004594 DNA Polymerase I Human genes 0.000 description 3
108010017826 DNA Polymerase I Proteins 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
108090000144 Human Proteins Proteins 0.000 description 3
102000003839 Human Proteins Human genes 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
108090001090 Lectins Proteins 0.000 description 3
102000004856 Lectins Human genes 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
239000007975 buffered saline Substances 0.000 description 3
239000013553 cell monolayer Substances 0.000 description 3
238000010382 chemical cross-linking Methods 0.000 description 3
238000010276 construction Methods 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
230000004927 fusion Effects 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
239000003999 initiator Substances 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000002523 lectin Substances 0.000 description 3
102000006240 membrane receptors Human genes 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
244000005700 microbiome Species 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000002482 oligosaccharides Polymers 0.000 description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
238000010839 reverse transcription Methods 0.000 description 3
238000002741 site-directed mutagenesis Methods 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
-1 sulfopropyl Chemical group 0.000 description 3
230000014621 translational initiation Effects 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
229930024421 Adenine Natural products 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 2
101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 2
JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102100029727 Enteropeptidase Human genes 0.000 description 2
108010013369 Enteropeptidase Proteins 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
229920000209 Hexadimethrine bromide Polymers 0.000 description 2
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
101150045458 KEX2 gene Proteins 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 2
NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 2
101800000135 N-terminal protein Proteins 0.000 description 2
101800001452 P1 proteinase Proteins 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
239000001888 Peptone Substances 0.000 description 2
108010080698 Peptones Proteins 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
239000004365 Protease Substances 0.000 description 2
239000012083 RIPA buffer Substances 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
241000235070 Saccharomyces Species 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
101150006914 TRP1 gene Proteins 0.000 description 2
108020005038 Terminator Codon Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
241000700605 Viruses Species 0.000 description 2
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000010306 acid treatment Methods 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000002518 antifoaming agent Substances 0.000 description 2
108010062796 arginyllysine Proteins 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical class [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
230000002500 effect on skin Effects 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
108010052968 leupeptin Proteins 0.000 description 2
108010054155 lysyllysine Proteins 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
108020004084 membrane receptors Proteins 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
229950000964 pepstatin Drugs 0.000 description 2
108010091212 pepstatin Proteins 0.000 description 2
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
235000019319 peptone Nutrition 0.000 description 2
239000012071 phase Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000006152 selective media Substances 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000002463 transducing effect Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102100023995 Beta-nerve growth factor Human genes 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282465 Canis Species 0.000 description 1
102000003846 Carbonic anhydrases Human genes 0.000 description 1
108090000209 Carbonic anhydrases Proteins 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
241000282324 Felis Species 0.000 description 1
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
108091029795 Intergenic region Proteins 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
241000235649 Kluyveromyces Species 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
102000008192 Lactoglobulins Human genes 0.000 description 1
108010060630 Lactoglobulins Proteins 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101100166423 Mus musculus Ccdc47 gene Proteins 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
102100027343 Napsin-A Human genes 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010065081 Phosphorylase b Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000235648 Pichia Species 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
239000012722 SDS sample buffer Substances 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
241001664469 Tibicina haematodes Species 0.000 description 1
LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000005273 aeration Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108010068380 arginylarginine Proteins 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
108010092854 aspartyllysine Proteins 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
238000009835 boiling Methods 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
230000006334 disulfide bridging Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
238000002270 exclusion chromatography Methods 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
239000011536 extraction buffer Substances 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
229940029303 fibroblast growth factor-1 Drugs 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
229920000140 heteropolymer Polymers 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000046157 human CSF2 Human genes 0.000 description 1
229940116978 human epidermal growth factor Drugs 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000005965 immune activity Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
230000010039 intracellular degradation Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000009343 monoculture Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000000734 protein sequencing Methods 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
238000003608 radiolysis reaction Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000012121 regulation of immune response Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000010242 retro-orbital bleeding Methods 0.000 description 1
239000007320 rich medium Substances 0.000 description 1
238000005185 salting out Methods 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
238000009738 saturating Methods 0.000 description 1
238000007790 scraping Methods 0.000 description 1
239000013606 secretion vector Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000001913 submandibular gland Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
108700004027 tat Genes Proteins 0.000 description 1
101150098170 tat gene Proteins 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
208000008732 thymoma Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229960001479 tosylchloramide sodium Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
239000007222 ypd medium Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Toxicology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

IL8847288A 1987-11-25 1988-11-24 Interleukin proteins) (SR1-LM in mammals, AND expression vectors that encode them, processes for their preparation and pharmaceutical preparations containing them IL88472A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12562787A	1987-11-25	1987-11-25
US07/160,550 US4968607A (en)	1987-11-25	1988-02-25	Interleukin-1 receptors

Publications (2)

Publication Number	Publication Date
IL88472A0 IL88472A0 (en)	1989-06-30
IL88472A true IL88472A (en)	1995-03-15

Family

ID=26823770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8847288A IL88472A (en)	1987-11-25	1988-11-24	Interleukin proteins) (SR1-LM in mammals, AND expression vectors that encode them, processes for their preparation and pharmaceutical preparations containing them

Country Status (9)

Country	Link
US (1)	US4968607A (de)
EP (2)	EP0318296B1 (de)
JP (1)	JP2753287B2 (de)
AT (1)	ATE169956T1 (de)
DE (1)	DE3856238T2 (de)
ES (1)	ES2122955T3 (de)
IE (1)	IE61563B1 (de)
IL (1)	IL88472A (de)
NZ (1)	NZ227059A (de)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6008217A (en) *	1995-12-20	1999-12-28	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β converting enzyme
US5874424A (en) *	1995-12-20	1999-02-23	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) *	1995-12-20	2001-03-20	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β Converting enzyme inhibitors
US5714585A (en) *	1987-10-26	1998-02-03	Sterling Winthrop, Inc.	Antibodies that are immunoreactive with interleukin-7
US5328988A (en) *	1987-10-26	1994-07-12	Immunex Corporation	Interleukin-7
US6511665B1 (en) *	1987-11-25	2003-01-28	Immunex Corporation	Antibodies to interleukin-1 receptors
US6858409B1 (en)	1988-05-27	2005-02-22	Amgen Inc.	Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en)	1988-05-27	1991-12-24	Synergen, Inc.	Interleukin-1 inhibitors
US6159460A (en) *	1988-05-27	2000-12-12	Amgen Inc.	Method for treating interleukin-1 mediated diseases
HU215581B (hu) *	1989-07-06	1999-01-28	Regents Of The University Of California	Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
US5106965A (en) *	1989-11-27	1992-04-21	Research Corporation Technologies, Inc.	Detection of human adenovirus
JPH06503719A (ja) *	1990-09-28	1994-04-28	イムネクス　コーポレイション	Ｔ↓ｈ依存性細胞障害性Ｔリンパ球の産生方法
US5470730A (en) *	1990-09-28	1995-11-28	Immunex	Method for producing TH -independent cytotoxic T lymphocytes
US6413511B1 (en)	1990-12-20	2002-07-02	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
CA2098848A1 (en) *	1990-12-20	1992-06-21	Joseph C. Glorioso	Truncated interleukin-1 receptor gene for the treatment of arthritis
US6228356B1 (en)	1990-12-20	2001-05-08	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
US6156304A (en) *	1990-12-20	2000-12-05	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Gene transfer for studying and treating a connective tissue of a mammalian host
US5858355A (en) *	1990-12-20	1999-01-12	University Of Pittsburgh Of The Commonwealth System Of Higher Education	IRAP gene as treatment for arthritis
US6159464A (en) *	1990-12-20	2000-12-12	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
WO1993007863A1 (en) *	1991-10-15	1993-04-29	Mullarkey Michael F	Methods and compositions for treating allergic reactions
ATE242322T1 (de) *	1992-03-30	2003-06-15	Immunex Corp	Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
US6582728B1 (en)	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en)	1992-07-08	2003-01-21	Inhale Therapeutic Systems, Inc.	Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6024090A (en)	1993-01-29	2000-02-15	Aradigm Corporation	Method of treating a diabetic patient by aerosolized administration of insulin lispro
US7448375B2 (en)	1993-01-29	2008-11-11	Aradigm Corporation	Method of treating diabetes mellitus in a patient
US5861476A (en) *	1994-02-02	1999-01-19	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) *	1994-02-02	1997-03-04	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) *	1994-02-02	1998-07-28	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) *	1994-02-02	1999-03-09	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-1 receptor
US6051256A (en) *	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
ATE416755T1 (de) *	1994-03-07	2008-12-15	Nektar Therapeutics	Verfahren und zusammensetzung für die pulmonale darreichung von insulin
JPH083058A (ja) *	1994-06-17	1996-01-09	Hoechst Japan Ltd	新規な骨代謝疾患治療剤
US5847135A (en) *	1994-06-17	1998-12-08	Vertex Pharmaceuticals, Incorporated	Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) *	1995-06-05	2002-07-16	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β converting enzyme
US5756466A (en) *	1994-06-17	1998-05-26	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1β converting enzyme
US5716929A (en) *	1994-06-17	1998-02-10	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1β converting enzyme
AU705595B2 (en) *	1994-09-09	1999-05-27	Neurocrine Biosciences, Incorporated	Interleukin-1 type 3 receptors
US6239268B1 (en)	1994-09-09	2001-05-29	Neurocrine Biosciences, Inc.	Interleukin-1 type 3 receptors
US7091181B2 (en)	1994-12-12	2006-08-15	Omeros Corporation	Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US5780014A (en) *	1995-04-14	1998-07-14	Inhale Therapeutic Systems	Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
DK1666591T3 (da)	1995-06-29	2011-05-23	Immunex Corp	Cytokin der inducerer apoptose
US5843904A (en) *	1995-12-20	1998-12-01	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1βconverting enzyme
US6410252B1 (en)	1995-12-22	2002-06-25	Case Western Reserve University	Methods for measuring T cell cytokines
US5939281A (en) *	1996-09-16	1999-08-17	Case Western Reserve University	Detecting alloreactivity
ES2312179T3 (es) *	1996-12-06	2009-02-16	Amgen Inc.	Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
US20030203036A1 (en)	2000-03-17	2003-10-30	Gordon Marc S.	Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
US7820383B2 (en) *	1997-03-10	2010-10-26	Interleukin Genetics, Inc.	Method for diagnosing myocardial infarction
US6524795B1 (en)	1997-03-10	2003-02-25	Interleukin Genetics, Inc.	Diagnostics for cardiovascular disorders
US6384203B1 (en)	1999-05-12	2002-05-07	Immunex Corporation	Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6063600A (en) *	1997-05-23	2000-05-16	Uab Research Foundation	DNA encoding canine interleukin-1 receptor antagonist
US6733967B1 (en)	1998-04-21	2004-05-11	Interleukin Genetics, Inc.	Fetal testing for prediction of low birth weight
DE69932247T2 (de) *	1998-08-21	2007-05-31	Immunex Corp., Thousand Oaks	Menschliches il-1 epsilon dna und polypeptide
ATE372126T1 (de) *	1998-11-05	2007-09-15	Omeros Corp	Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung
US20090023147A1 (en) *	1999-08-30	2009-01-22	Kenneth Kornman	Diagnostics and therapeutics for osteoporosis
US6346247B1 (en)	1999-10-28	2002-02-12	Promega Corporation	Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP2298333A3 (de)	1999-12-20	2012-05-02	Immunex Corporation	Tweak Rezeptor
TWI322154B (en)	2000-03-16	2010-03-21	Amgen Inc	Il-17 receptor like molecules and uses thereof
EP1712239A3 (de) *	2000-05-12	2007-08-22	Immunex Corporation	Interleukin-1 Inhibitoren zur Behandlung von Erkrankungen
US7575761B2 (en)	2000-06-30	2009-08-18	Novartis Pharma Ag	Spray drying process control of drying kinetics
US20030040119A1 (en) *	2001-04-11	2003-02-27	The Regents Of The University Of Michigan	Separation devices and methods for separating particles
US20050152902A1 (en) *	2001-06-05	2005-07-14	Advanced Biotherapy, Inc.	Treatment of diabetic retinopathy
CA2450809A1 (en) *	2001-06-15	2002-12-27	Interleukin Genetics, Inc.	Methods for detecting and treating the early onset of aging-related conditions
EP2295081B1 (de)	2001-06-26	2018-10-31	Amgen Inc.	Antikörper gegen OPGL
DE60232742D1 (de)	2001-10-04	2009-08-06	Immunex Corp	Ul16-bindungsprotein 4
WO2003044176A2 (en) *	2001-11-19	2003-05-30	Interleukin Genetics, Inc.	Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
US20080311581A1 (en) *	2001-11-19	2008-12-18	David Wyllie	Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
US20070264645A1 (en) *	2002-01-25	2007-11-15	Kenneth Kornman	IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
CA2480121C (en)	2002-03-27	2012-02-28	Immunex Corporation	Methods for increasing polypeptide production
GB0216562D0 (en)	2002-04-25	2002-08-28	Bradford Particle Design Ltd	Particulate materials
US9339459B2 (en)	2003-04-24	2016-05-17	Nektar Therapeutics	Particulate materials
KR101317045B1 (ko) *	2002-09-06	2013-10-16	암젠 인코포레이티드	치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
WO2004034988A2 (en)	2002-10-16	2004-04-29	Amgen Inc.	Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
WO2004060911A2 (en)	2002-12-30	2004-07-22	Amgen Inc.	Combination therapy with co-stimulatory factors
US20050232931A1 (en) *	2003-06-13	2005-10-20	Oncomax Acquisition Corp.	Preparation and application of anti-tumor bifunctional fusion proteins
US20040254108A1 (en) *	2003-06-13	2004-12-16	Jing Ma	Preparation and application of anti-tumor bifunctional fusion proteins
EP2133362B1 (de)	2003-07-25	2012-04-18	Amgen, Inc	Verfahren bezüglich LDCAM und CRTAM
CA2534365A1 (en) *	2003-08-08	2005-02-17	Interleukin Genetics, Inc.	Diagnostic and therapeutics for osteoporosis
RS57852B1 (sr) *	2004-04-02	2018-12-31	Swedish Orphan Biovitrum Ab Publ	Postupci za smanjenje agregacije il-1ra
US20050276807A1 (en) *	2004-06-15	2005-12-15	Advanced Biotherapy, Inc.	Treatment of acne
US7462454B2 (en) *	2004-10-12	2008-12-09	Advanced Biotherapy, Inc.	Treatment of herpes
MX2007006593A (es) *	2004-12-02	2008-03-04	Domantis Ltd	Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
US8105775B2 (en) *	2005-10-25	2012-01-31	Interleukin Genetics, Inc.	IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
TW200736277A (en)	2005-11-14	2007-10-01	Amgen Inc	RANKL antibody-PTH/PTHrP chimeric molecules
EA200801166A1 (ru) *	2005-12-01	2008-12-30	Домантис Лимитед	Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
US8129334B2 (en)	2006-03-31	2012-03-06	The Regents Of The University Of California	Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
EP2500416A1 (de)	2006-09-13	2012-09-19	Abbott Laboratories	Verbesserungen an Zellkulturen
AU2007294731B2 (en)	2006-09-13	2014-04-17	Abbvie Inc.	Cell culture improvements
US7767206B2 (en)	2006-10-02	2010-08-03	Amgen Inc.	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2089538B1 (de) *	2006-11-15	2013-08-21	Interleukin Genetics, Inc.	Il-1-gen-cluster und insulinresistenz: assoziierte polymorphismen und haplotypen sowie verwendungsverfahren dafür
PL2188313T3 (pl)	2007-08-21	2018-04-30	Amgen, Inc.	Białka wiążące ludzki antygen c-fms
TW200918553A (en)	2007-09-18	2009-05-01	Amgen Inc	Human GM-CSF antigen binding proteins
US20090170105A1 (en) *	2007-11-08	2009-07-02	Interleukin Genetics, Inc.	Diagnostics for Aging-Related Dermatologic Disorders
EP2304052A2 (de) *	2008-05-02	2011-04-06	Interleukin Genetics, Inc.	Nachweis von genetischer veranlagung für osteoarthritische erkrankungen
JP5762282B2 (ja)	2008-05-02	2015-08-12	インタールーキンジェネティクス，インコーポレイテッド	変形性関節症に関連する状態に対する遺伝的素因の検出
EP2285409B1 (de)	2008-05-30	2016-04-20	XBiotech, Inc	Il-1-alpha-antikörper
JO3382B1 (ar)	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
TW201117824A (en)	2009-10-12	2011-06-01	Amgen Inc	Use of IL-17 receptor a antigen binding proteins
JO3244B1 (ar)	2009-10-26	2018-03-08	Amgen Inc	بروتينات ربط مستضادات il – 23 البشرية
WO2011060242A2 (en)	2009-11-13	2011-05-19	Talecris Biotherapeutics, Inc.	Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
UA109888C2 (uk)	2009-12-07	2015-10-26		ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US20130101590A1 (en)	2010-04-09	2013-04-25	Heather A. Arnett	Btnl9 proteins, nucleic acids, and antibodies and uses thereof
CA2796055A1 (en)	2010-04-15	2011-10-20	Amgen Inc.	Human fgf receptor and .beta.-klotho binding proteins
EP2582391B1 (de)	2010-06-18	2018-10-03	XBiotech, Inc	Arthritis-behandlung
SG187198A1 (en)	2010-08-05	2013-03-28	Amgen Inc	Dipeptides to enhance yield and viability from cell cultures
KR101910760B1 (ko)	2010-08-23	2018-10-22	엑스바이오테크, 인크.	종양성 질병들에 대한 치료
CA2828405A1 (en)	2011-02-28	2012-09-07	Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale	Apoptosis-inducing molecules and uses therefor
US9724409B2 (en)	2011-04-01	2017-08-08	Xbiotech, Inc.	Treatment of inflammatory skin disease
WO2012145682A1 (en)	2011-04-21	2012-10-26	Amgen Inc.	A method for culturing mammalian cells to improve recombinant protein production
US9574002B2 (en)	2011-06-06	2017-02-21	Amgen Inc.	Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
PT2837680T (pt)	2011-07-01	2020-04-17	Amgen Inc	Cultura celular de mamífero
WO2013016220A1 (en)	2011-07-22	2013-01-31	Amgen Inc.	Il-17 receptor a is required for il-17c biology
JP2014529473A (ja)	2011-09-02	2014-11-13	アムジエン・インコーポレーテツド	医薬製品および医薬製品の露光を分析する方法
MX353958B (es)	2011-09-22	2018-02-07	Amgen Inc	Proteinas de union al antigeno cd27l.
JP6635655B2 (ja)	2011-12-08	2020-01-29	アムジエン・インコーポレーテツド	ヒトｌｃａｔ抗原結合タンパク質および治療法におけるそれらの使用
AR089231A1 (es)	2011-12-15	2014-08-06	Amgen Inc	Metodo de floculacion
US9926373B2 (en)	2012-04-27	2018-03-27	Novo Nordisk A/S	Human CD30 ligand antigen binding proteins
AR091069A1 (es)	2012-05-18	2014-12-30	Amgen Inc	Proteinas de union a antigeno dirigidas contra el receptor st2
EP2875046B2 (de)	2012-07-19	2025-04-30	Amgen Inc.	Humane btnl3-proteine, nukleinsäuren sowie antikörper und verwendungen davon
US9309318B2 (en)	2012-10-17	2016-04-12	Amgen, Inc.	Compositions relating to anti-IL-21 receptor antibodies
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
KR20150093775A (ko)	2012-12-07	2015-08-18	노쓰 캐롤라이나 스테이트 유니버시티	베타 헥소실-전이효소 및 이의 이용
TW201425336A (zh)	2012-12-07	2014-07-01	Amgen Inc	Ｂｃｍａ抗原結合蛋白質
US20150353542A1 (en)	2013-01-14	2015-12-10	Amgen Inc.	Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US10023608B1 (en)	2013-03-13	2018-07-17	Amgen Inc.	Protein purification methods to remove impurities
SI3395423T1 (sl)	2013-03-14	2023-12-29	Amgen Inc.	Odstranjevanje izluženega liganda za afinitetno čiščenje
TWI832345B (zh)	2013-03-14	2024-02-11	美商安美基公司	用於增加重組蛋白質之甘露糖含量之方法
US9580486B2 (en)	2013-03-14	2017-02-28	Amgen Inc.	Interleukin-2 muteins for the expansion of T-regulatory cells
EP2970451A1 (de)	2013-03-14	2016-01-20	Amgen Inc.	Chrdl-1-antigenbindende proteine und behandlungsmethoden damit
US9708375B2 (en)	2013-03-15	2017-07-18	Amgen Inc.	Inhibitory polypeptides specific to WNT inhibitors
EP2970483A2 (de)	2013-03-15	2016-01-20	Amgen Inc.	Verfahren und zusammensetzungen im zusammenhang mit anti-ccr7-antigen-bindenden proteinen
US9850297B2 (en)	2013-03-15	2017-12-26	Amgen Inc.	Secreted frizzle-related protein 5 (SFRP5) binding proteins
CA2906737C (en)	2013-03-15	2023-08-15	Amgen Inc.	Human pac1 antibodies
US9481901B2 (en)	2013-05-30	2016-11-01	Amgen Inc.	Methods for increasing mannose content of recombinant proteins
HUE056580T2 (hu)	2013-05-30	2022-02-28	Kiniksa Pharmaceuticals Ltd	Onkosztatin-M-receptor antigénjét kötõ fehérjék
TW201605896A (zh)	2013-08-30	2016-02-16	安美基股份有限公司	Gitr抗原結合蛋白
EP3041863A4 (de)	2013-09-05	2017-08-16	Amgen Inc.	Fc-haltige moleküle mit vorhersagbaren, konsistenten und reproduzierbaren glycoformprofilen
US20160257748A1 (en)	2013-09-25	2016-09-08	Amgen Inc.	V-c-fc-v-c antibody
RS66894B1 (sr)	2013-10-31	2025-07-31	Amgen Inc	Upotreba monensina za regulaciju glikozilacije rekombinantnih proteina
BR122020004385B1 (pt)	2014-01-13	2022-10-04	Amgen Inc	Método para aumentar o teor de glicoforma de alta manose de uma glicoproteína recombinante e método de produção de uma glicoproteína recombinante
US10106829B2 (en)	2014-01-29	2018-10-23	Amgen Inc.	Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
WO2015116315A1 (en)	2014-01-29	2015-08-06	Amgen Inc.	Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
WO2015127134A2 (en)	2014-02-20	2015-08-27	Allergan, Inc.	Complement component c5 antibodies
CN110724691A (zh)	2014-02-27	2020-01-24	阿勒根公司	补体因子Bb抗体
AU2015269365A1 (en)	2014-06-04	2016-12-15	Amgen Inc.	Methods for harvesting mammalian cell cultures
WO2016044224A1 (en)	2014-09-15	2016-03-24	Amgen Inc.	Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
US11275090B2 (en)	2014-11-19	2022-03-15	Amgen Inc.	Quantitation of glycan moiety in recombinant glycoproteins
CA2969225C (en)	2014-12-01	2023-08-22	Amgen Inc.	Process for manipulating the level of glycan content of a glycoprotein
CR20170510A (es)	2015-04-10	2018-02-26	Amgen Inc	Muteínas de interuquina 2 para la expansión de células t regulatorias
TWI799849B (zh)	2015-04-24	2023-04-21	美商安美基公司	治療或預防偏頭痛之方法
WO2016172485A2 (en)	2015-04-24	2016-10-27	Genentech, Inc.	Multispecific antigen-binding proteins
CA2998174A1 (en)	2015-09-15	2017-03-23	Amgen Inc.	Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
EP3699269A1 (de)	2015-09-22	2020-08-26	F. Hoffmann-La Roche AG	Expression von fc-haltigen proteinen
ES2875274T3 (es)	2015-11-02	2021-11-10	Hoffmann La Roche	Procedimientos de preparación de formas fucosiladas y afucosiladas de una proteína
US10822408B2 (en)	2015-12-15	2020-11-03	Amgen Inc.	PACAP antibodies and uses thereof
UA127495C2 (uk)	2015-12-23	2023-09-13	Амджен Інк.	Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
JP7422480B2 (ja)	2016-05-04	2024-01-26	アムジエン・インコーポレーテツド	制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
KR102579850B1 (ko)	2016-07-22	2023-09-18	암젠 인크	Fc-함유 단백질의 정제 방법
WO2018022982A1 (en)	2016-07-29	2018-02-01	Trustees Of Boston University	Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
MX2019005552A (es)	2016-11-14	2019-08-12	Amgen Inc	Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
BR112019013953A2 (pt)	2017-01-06	2020-02-11	Abl Bio Inc.	Anticorpo anti-a-syn e uso do mesmo
EP3567054A4 (de)	2017-01-06	2021-03-10	ABL Bio Inc.	Anti-alpha-syn-antikörper und verwendung davon
IL313587A (en)	2017-01-17	2024-08-01	Amgen Inc	Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
EP3582813A4 (de)	2017-02-16	2020-12-30	XBiotech, Inc	Behandlung von hidradenitis suppurativa
JOP20190248A1 (ar)	2017-04-21	2019-10-20	Amgen Inc	بروتينات ربط مولد ضد trem2 واستخداماته
JOP20190259A1 (ar)	2017-05-31	2019-10-31	Amgen Inc	بروتينات ربط مولد ضد مضادة لـ jagged1
EA201992502A1 (ru)	2017-06-20	2020-04-22	Эмджен Инк.	Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
EP3642238A1 (de)	2017-06-21	2020-04-29	Amgen Inc.	Verfahren zur behandlung oder linderung von stoffwechselstörungen unter verwendung von antagonistischen bindungsproteinen für rezeptoragonistfusionsproteine des gastrischen inhibitorpeptidrezeptors (gipr)/glp-1
LT3661562T (lt)	2017-08-04	2024-10-25	Amgen Inc.	Cys-mab konjugavimo būdas
EP3725806A4 (de)	2017-12-14	2022-03-30	ABL Bio Inc.	Bispezifischer antikörper gegen a-syn/igf1r und seine verwendung
SG11202006610YA (en)	2018-01-12	2020-08-28	Amgen Inc	Pac1 antibodies and uses thereof
IL307155B2 (en)	2018-05-01	2025-11-01	Amgen Inc	Antibodies with modulated glycan profiles
WO2019225777A1 (ko)	2018-05-23	2019-11-28	에이비엘바이오 주식회사	항-ror1 항체 및 그 용도
WO2019225787A1 (ko)	2018-05-24	2019-11-28	에이비엘바이오 주식회사	항-b7-h3 항체 및 그 용도
US12403181B2 (en)	2018-08-13	2025-09-02	Iltoo Pharma	Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
AU2019398101B2 (en)	2018-12-10	2025-12-18	Amgen Inc.	Mutated piggybac transposase
JP7500619B2 (ja)	2019-05-30	2024-06-17	アムジエン・インコーポレーテツド	抗体の二量体化を促進するためのヒンジ領域の操作
US20220363770A1 (en)	2019-06-28	2022-11-17	Amgen Inc.	Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
PH12022550326A1 (en)	2019-08-13	2023-03-13	Amgen Inc	Interleukin-2 muteins for the expansion of t-regulatory cells
WO2021091906A1 (en)	2019-11-04	2021-05-14	Amgen Inc.	Methods for treating leukemia
ES3040852T3 (en)	2019-11-08	2025-11-05	Amgen Inc	Engineering charge pair mutations for pairing of hetero-igg molecules
AU2020386005A1 (en)	2019-11-19	2022-05-26	Amgen Inc.	Novel multispecific antibody format
IL293471A (en)	2019-12-17	2022-08-01	Amgen Inc	Dual interleukin-2 / tnf receptor agonist for use in medicine
IL293640A (en)	2019-12-20	2022-08-01	Amgen Inc	CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
US20230322955A1 (en)	2020-08-20	2023-10-12	Amgen Inc.	Antigen binding proteins with non-canonical disulfide in fab region
US20230374162A1 (en)	2020-10-07	2023-11-23	Amgen Inc.	Rational selection of building blocks for the assembly of multispecific antibodies
TW202233660A (zh)	2020-10-30	2022-09-01	美商安進公司	過表現胰島素樣生長因子受體突變體以調節ｉｇｆ補充
WO2022103773A1 (en)	2020-11-10	2022-05-19	Amgen Inc.	Novel linkers of multispecific antigen binding domains
MX2023012324A (es)	2021-04-20	2023-10-30	Amgen Inc	Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.
WO2022232376A1 (en)	2021-04-29	2022-11-03	Amgen Inc.	Methods for reducing low molecular weight species of recombinantly-produced proteins
CA3222782A1 (en)	2021-06-10	2022-12-15	Amgen Inc.	Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3
TW202328442A (zh)	2021-09-10	2023-07-16	美商安進公司	平臺宿主對ｉｇｆ—培養基之適應
AU2022424002A1 (en)	2021-12-29	2024-06-13	Bristol-Myers Squibb Company	Generation of landing pad cell lines
AU2023231637A1 (en)	2022-03-09	2024-09-05	Amgen Inc.	Optimized transfection protocol
EP4406973A1 (de)	2023-01-27	2024-07-31	Fundació Privada Institut de Recerca de la SIDA-Caixa	Antikörper und verwendungen davon zur behandlung von infektionen durch eingehüllte viren
EP4735476A1 (de)	2023-06-27	2026-05-06	Amgen Inc.	Ladungspaarmutationen zur ermöglichung der korrekten schwerleichtkettenpaarung
US20250027052A1 (en)	2023-07-21	2025-01-23	Amgen Inc.	Vectors incorporating a combination of promoters driving selectable marker expression
AU2024363859A1 (en)	2023-10-18	2026-04-09	Amgen Inc.	Evaluation of mrna transcript levels using ddpcr for early pool and single-cell clone assessment in cell line development
WO2025155774A2 (en)	2024-01-19	2025-07-24	Amgen Inc.	Vector engineering strategies to enhance volumetric productivity and decrease impurity formation across a diverse set of modalities
WO2025155776A1 (en)	2024-01-19	2025-07-24	Amgen Inc.	Expression vector systems with two copies of light chain
TW202548027A (zh)	2024-01-23	2025-12-16	美商安進公司	用於調節單株抗體電荷變體之方法
WO2025184493A1 (en)	2024-02-29	2025-09-04	Amgen Inc.	Dual selection expression vector systems for multi-chain biologics
WO2025199030A1 (en)	2024-03-18	2025-09-25	Amgen Inc.	Glp-1 receptor agonists and their medical use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1339269C (en) *	1984-05-21	1997-08-12	Douglas P. Cerretti	Purification of and cloning of the gene for interleukin-2 receptor
US4675285A (en) *	1984-09-19	1987-06-23	Genetics Institute, Inc.	Method for identification and isolation of DNA encoding a desired protein

1988
- 1988-02-25 US US07/160,550 patent/US4968607A/en not_active Expired - Lifetime
- 1988-11-23 NZ NZ227059A patent/NZ227059A/en unknown
- 1988-11-24 EP EP88311150A patent/EP0318296B1/de not_active Expired - Lifetime
- 1988-11-24 EP EP94109298A patent/EP0623674A1/de not_active Withdrawn
- 1988-11-24 IE IE352388A patent/IE61563B1/en not_active IP Right Cessation
- 1988-11-24 DE DE3856238T patent/DE3856238T2/de not_active Expired - Lifetime
- 1988-11-24 AT AT88311150T patent/ATE169956T1/de not_active IP Right Cessation
- 1988-11-24 IL IL8847288A patent/IL88472A/en not_active IP Right Cessation
- 1988-11-24 ES ES88311150T patent/ES2122955T3/es not_active Expired - Lifetime
- 1988-11-25 JP JP63298001A patent/JP2753287B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
IE883523L (en)	1989-05-25
DE3856238D1 (de)	1998-09-24
IE61563B1 (en)	1994-11-16
EP0318296A3 (de)	1991-09-18
JP2753287B2 (ja)	1998-05-18
EP0318296B1 (de)	1998-08-19
DE3856238T2 (de)	1999-04-15
NZ227059A (en)	1990-12-21
ATE169956T1 (de)	1998-09-15
EP0623674A1 (de)	1994-11-09
ES2122955T3 (es)	1999-01-01
JPH022351A (ja)	1990-01-08
US4968607A (en)	1990-11-06
EP0318296A2 (de)	1989-05-31
IL88472A0 (en)	1989-06-30

Legal Events

Date	Code	Title
1999-04-11	KB	Patent renewed
2003-01-12	KB	Patent renewed
2006-12-27	KB	Patent renewed
2009-07-20	EXP	Patent expired

Publication	Publication Date	Title
EP0318296B1 (de)	1998-08-19	DNA, die für Proteine kodiert, die menschliches IL-1 binden
US5081228A (en)	1992-01-14	Interleukin-1 receptors
CA1341611C (en)	2011-04-12	Interleukin-1 receptors
US5319071A (en)	1994-06-07	Soluble interleukin-1 receptors
AU643427B2 (en)	1993-11-18	Interleukin-4 receptors
EP0817847B2 (de)	2009-09-09	Il-17 receptor
EP0460846B1 (de)	2002-02-27	Typ-II-Interleukin-1-Rezeptoren
US5705149A (en)	1998-01-06	Use of interleukin-7 to stimulate proliferation of hematopoietic cell precursors
US7863019B2 (en)	2011-01-04	Interleukin-15 receptors
IE903467A1 (en)	1991-04-10	Granulocyte-colony stimulating factor receptors
US5296592A (en)	1994-03-22	Process for purifying interleukin-1 receptors
US7432237B2 (en)	2008-10-07	Methods of treating asthma by administering interleukin-17 receptor
AU625534B2 (en)	1992-07-16	Interleukin-1 receptors
US5223605A (en)	1993-06-29	Interleukin-4 binding protein-γ
DK175810B1 (da)	2005-03-07	Interleukin-1 receptor
CA1340761C (en)	1999-09-21	Interleukin-4-receptors